Jonathan Jay Mazelsky

Director Jonathan Jay Mazelsky bought 10,000 shares of XRAY at $10.14; cluster of 5 other insiders bought within 14 days; stock trading -39.6% from 52-week high.

Jonathan Jay Mazelsky purchased 10,000 shares at $10.14, increasing his holdings from 51,668 shares to 61,668 shares on 2026-06-12. This transaction is part of a cluster pattern in which 5 other insiders also bought within the past 14 days. The stock is currently trading at $10.33, down -39.6% from its 52-week high of $17.09, and the company reported a net loss of $-10,000,000.00 on revenue of $880,000,000.00 in the latest quarter. The convergence of multiple insider purchases during a period of depressed valuation and negative earnings warrants investor attention to what prompted the synchronized buying activity.

CEO Mazelsky sells 23,326 shares of IDXX for $15.3M across 13 transactions on 2026-02-26; stock down 5.0% (30d), 13.1% (90d), trading 17.0% below 52-week high

Jonathan Jay Mazelsky, President and CEO of IDEXX Laboratories, executed 13 separate sales totaling 23,326 shares for $15,338,080.79 at prices ranging from $650.67 to $662.16. This represents a -21.8% reduction in his post-transaction holdings to 83,803 shares. The transaction occurred as IDXX traded at $657.55 (blended average price) while currently trading at $636.70, and the stock has declined 5.0% over the preceding 30 days and 13.1% over the preceding 90 days. His prior five IDXX sales (all on 2025-08-06) yielded positive 90-day returns of +12.9%, +14.9%, +14.6%, +14.5%, and +14.3%, indicating those sales were poorly timed relative to subsequent price appreciation. The current filing's timing relative to forward returns cannot yet be assessed, but investors should note the substantial scale of this position reduction and the recent price deterioration in the name.

CEO Jonathan Mazelsky sells 29,260 shares ($18.5M) at $626.90–$639.37; reduces holdings 26.0% to 83.3K shares

Jonathan Mazelsky, President and CEO of IDXX, executed 10 separate sales on 2025-08-06 totaling 29,260 shares for $18,491,642.25, reducing his holdings from 112,571 to 83,311 shares (a 26.0% reduction). The transaction prices ranged from $626.90 to $639.37, with a blended average of $631.98, occurring near the stock's 52-week high of $682.78 (current price $658.06, down 3.6% from peak). Notably, his prior 5 sales at IDXX between February 2024 and the present were all well-timed at the 90-day mark, with each generating negative 90-day returns ranging from -15.4% to -16.0%, and his cross-ticker track record across 8 prior sells shows a 75.00% well-timed rate. The stock has appreciated 21.7% in the past 30 days and 33.8% over 90 days, creating a valuation context in which the CEO is executing a material reduction in his principal holdings.